Medical Need

Diabetic foot ulcer & chronic wounds


Pressing need for novel and effective therapies

  • Leading cause of hospitalizations in diabetes
  • 75% of all amputations are diabetic patients
  • Only 21% of patients with lower leg amputation survive a 5 year period
  • 50 Mio out of 370 Mio diabetics patients are affected
  • Huge burden to patients and payors (€ 12 bn p.a.)


Current Therapies with Limited Success

  • Negative Pressure
  • Skin Substitutes
  • Oxygen
  • Growth factors (Becaplermin/only USA)





Strategic Options for the Future:

Outlicensing of other ground-breaking

TOPADUR medical pipeline compounds :



  • Glaucoma (Project ‘Vistadur’ as per 2019) – strategic opthalhmology research & development analysis to further evaluate inherent product potential
  • ED (erectile dysfunction) – Topical
  • Pulmonary Arterial Hypertension


IP rights:

  • Strong IP position

Scar & keloid prevention


Strong Need for Innovative, Antifibrotic and Anti-Inflammatory Treatments

  • Up to 15% of general population affected with hypertrophic scars following wounds
  • 70% of patients with burns develop hypertrophic scars
  • Keloids occur to 5-16% in high risk populations e.g. asian, african, hispanic
  • € 12 bn treatment costs p.a.


Current Therapies with Limited Success

  • Corticosteroids (triamcinolone)
  • 5-Fluorouracil
  • Cryotherapy
  • Surgery